Pasithea Therapeutics (KTTA) Gains from Sales and Divestitures (2021 - 2023)
Pasithea Therapeutics recorded quarterly Gains from Sales and Divestitures of $5832.0 in Q4 2023, down 94.17% quarter-over-quarter from $100000.0 in Q4 2021.
Pasithea Therapeutics' Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $5832.0 for Q4 2023.
- In Q4 2023, Gains from Sales and Divestitures changed N/A year-over-year to $5832.0; the TTM figure through Dec 2023 stood at $5832.0 (changed N/A YoY), while the FY2023 annual figure was $5832.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $5832.0 for Q4 2023 at Pasithea Therapeutics, down from $100000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $100000.0 in Q4 2021 to a low of $5832.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 5,832.00 |
| Dec 31, 2023 | 5,832.00 |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |